参考文献/References:
[1]. Saklayen MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018,20(2):12.
[2].[] Verboven K,Hansen D,Jocken JWE,et al. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity[J]. Obes Rev,2017,18(11):1243-1259.
[3].[] Dessì-Fulgheri P,Sarzani R,Rappelli A. Role of the natriuretic peptide system in lipogenesis/lipolysis[J]. Nutr Metab Cardiovasc Dis,2003,13(4):244-249.
[4].[] Ahued-Ortega JA,León-García PE,Hernández-Pérez E. Correlation of plasma B-type natriuretic peptide levels with metabolic risk markers[J]. Med Clin (Barc),2018,151(12):481-486.
[5].[] Fu S,Ping P,Wang F,et al. Synthesis,secretion,function,metabolism and application of natriuretic peptides in heart failure[J]. J Biol Eng,2018,12(1):2.
[6].[] Lee CYW,Burnett JC. Natriuretic peptides and therapeutic applications[J]. Heart Fail Rev,2007,12 (2):131-142.
[7].[] Coué M,Moro C. Natriuretic peptide control of energy balance and glucose homeostasis[J]. Biochimie, 2016,124:84-91.
[8].[] Matsuo A,Nagai-Okatani C,Nishigori M,et al. Natriuretic peptides in human heart:Novel insight into their molecular forms, functions,and diagnostic use[J]. Peptides,2019,111:3-17.
[9].[] Wang TJ,Larson MG,Levy D,et al. Impact of obesity on plasma natriuretic peptide levels[J]. Circulation, 2004,109(5):594-600.
[10].[] Gentili A,Frangione MR,Albini E,et al. Modulation of natriuretic peptide receptors in human adipose tissue:molecular mechanisms behind the“natriuretic handicap”in morbidly obese patients[J]. Transl Res,2017,186:52-61.
[11].[] Suthahar N,Meijers WC,Ho JE,et al. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population[J]. Eur J Heart Fail,2018,20(8):1205-1214.
[12].[] Del Ry S,Cabiati M,Bianchi V,et al. C-type natriuretic peptide is closely associated to obesity in Caucasian adolescents[J]. Clin Chim Acta,2016,460:172-177.
[13].[] Bae CR,Hino J,Hosoda H,et al. Adipocyte-specific expression of C-type natriuretic peptide suppresses lipid metabolism and adipocyte hypertrophy in adipose tissues in mice fed high-fat diet[J]. Sci Rep, 2018,8(1):2093.
[14].[] Coué M, Barquissau V, Morigny P,et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes[J]. Sci Rep,2018,8(1):1097.
[15].[] Bordicchia M,Ceresiani M,Pavani M,et al. Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway[J]. Am J Physiol Regul Integr Comp Physiol,2016,311(1):R104-R114.
[16].[] Kim F,Biggs ML,Kizer JR,et al. Brain natriuretic peptide and insulin resistance in older adults[J]. Diabet Med,2017,34(2):235-238.
[17].[] Coué M,Moro C. Natriuretic peptide control of energy balance and glucose homeostasis[J]. Biochimie, 2016,124:84-91.
[18].[] Wu W,Shi F,Liu D,et al. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance[J]. Sci Signal,2017,10(489):E6870.
[19].[] Gruden G,Landi A, Bruno G. Natriuretic peptides,heart, and adipose tissue:new findings and future developments for diabetes research[J]. Diabetes Care,2014,37(11):2899-2908.
[20].[] Benomar K,Espiard S,Loyer C,et al. Atrial natriuretic hormones and metabolic syndrome: recent advances[J]. Presse Med,2018,47(2):116-124.
[21].[] Bae CR,Hino J,Hosoda H,et al. Overexpression of C-type natriuretic peptide in endothelial cells protects against insulin resistance and inflammation during diet-induced obesity[J]. Sci Rep,2017,7(1):9807.
[22].[]上官娇玲,凌智瑜. 心血管疾病风险指标新进展[J]. 心血管病学进展,2019,40(2):59-63.
[23].[] Zhang T,Chen J,Tang X,et al. Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis[J]. Lipids Health Dis,2019,18(1):223.
[24].[] Masuch A,Pietzner M,Bahls M,et al. Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP[J]. Cardiovasc Diabetol,2018,17(1):120.
[25].[] Wang JH,Lee CJ,Hsieh JC,et al. Serum atrial natriuretic peptide level inversely associates with metabolic syndrome in older adults[J]. Geriatr Gerontol Int,2014,14(3):640-646.
[26].[] He WT,Mori M,Yu XF,et al. Higher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional study[J]. Lipids Health Dis,2016,15:3.
[27].[] Spannella F,Giulietti F,Cocci G,et al. N-terminal pro B-Type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly[J]. Nutr Metab Cardiovasc Dis,2018,28(6): 629-635.
[28].[] Goharian TS,Goetze JP,Faber J,et al. Associations of proatrial natriuretic peptide with components of the metabolic syndrome in adolescents and young adults from the general population[J]. Am J Hypertens,2017,30(6):561-568.
[29].[] Rubattu S,Sciarretta S,Ciavarella GM,et al. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass[J]. J Hypertens,2007,25(4):833-839.
[30].[] Asferg CL,Andersen UB,Linneberg A,et al. Serum proatrial natriuretic peptide does not increase with higher systolic blood pressure in obese men[J]. Heart,2017,103(2):154-158.
[31].[] Davogustto G,Wang TJ,Gupta DK. Untangling essential hypertension:the potential roles of aldosterone and atrial natriuretic peptide[J]. Mayo Clin Proc,2018,93(8):965-967.
[32].[] Cannone V, Cabassi A, Volpi R,et al. Atrial natriuretic peptide:a molecular target of novel therapeutic approaches to cardio-metabolic disease[J]. Int J Mol Sci,2019,20(13):3265.
[33].[] Vandenwijngaert S,Ledsky CD,Lahrouchi N,et al. Blood pressure-associated genetic variants in the natriuretic peptide receptor 1 gene modulate guanylate cyclase activity.[J]. Circ Genom Precis Med,2019, 12(8):e002472.
[34].[] Bie P. Natriuretic peptides and normal body fluid regulation[J]. Compr Physiol,2018,8(3): 1211-1249.
[35].[] Jordan J,Stinkens R,Jax T,et al. Improved Insulin sensitivity with angiotensin receptor neprilysin Inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther,2017,101(2): 254-263.
相似文献/References:
[1]王海星,尹德春,曲秀芬.病态窦房结综合征的心房纤维化血清学指标研究进展[J].心血管病学进展,2020,(3):310.[doi:10.16806/j.cnki. issn.1004-3934.2020.03.023]
WANG Haixing,YIN Dechun,QU Xiufen.Serological Indicators of Atrial Fibrosis for Sick Sinus Syndrome[J].Advances in Cardiovascular Diseases,2020,(10):310.[doi:10.16806/j.cnki. issn.1004-3934.2020.03.023]
[2]任蕾 夏芳芳 戴红艳.血管生成素样蛋白6在心血管病方面的研究进展[J].心血管病学进展,2020,(4):388.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
REN Lei,XIA FangFang,DAI HongYan.Relationship Between ANGPTL6 and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):388.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
[3]薛建强 刘玉萍 倪国华 孙颖 孙平.60岁以上人群身体测量指标对代谢综合征的预测价值[J].心血管病学进展,2022,(10):947.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.019]
XUE Jianqiang,LIU Yuping,NI Guohua,et al.Predictive Value of Body Measurements for Metabolic Syndrome in People Over 60 Years of Age[J].Advances in Cardiovascular Diseases,2022,(10):947.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.019]
[4]贾朗 张伟 薛艳 陈娅君 汪汉 谢江.幼年特发性关节炎和代谢综合征各组分的相关性研究[J].心血管病学进展,2024,(6):571.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.021]
JIA Lang,ZHANG Wei,XUE Yan,et al.The Relationship Between Juvenile Idiopathic Arthritis and Various Components of?he Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2024,(10):571.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.021]
[5]白慧茹 庞建中.心血管-肾脏-代谢综合征的提出与临床现状[J].心血管病学进展,2025,(12):1071.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.004]
BAI Huiru,PANG Jianzhong.Proposal and Clinical Status of Cardiovascular-Kidney-Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2025,(10):1071.[doi:10.16806/j.cnki.issn.1004-3934.2025.12.004]